Amylyx Pharmaceuticals (AMLX) Total Current Liabilities (2021 - 2026)
Amylyx Pharmaceuticals (AMLX) posted quarterly Total Current Liabilities of $16.0 million for Q1 2026, down 10.96% year-over-year from $17.9 million in Q1 2025, and down 29.63% quarter-over-quarter from $22.7 million in Q4 2025.
Amylyx Pharmaceuticals (AMLX) Total Current Liabilities (2021 - 2026) Analysis & Trends
Amylyx Pharmaceuticals' Total Current Liabilities history runs 6 years deep, the most recent figure standing at $16.0 million for Q1 2026.
- In Q1 2026, Total Current Liabilities fell 10.96% year-over-year to $16.0 million; the TTM figure through Mar 2026 stood at $16.0 million (down 10.96% YoY), while the FY2025 annual figure was $22.7 million, down 20.13% from the prior year.
- Total Current Liabilities for Q1 2026 stood at $16.0 million, down from $22.7 million in the prior quarter.
- The five-year high for Total Current Liabilities was $91.6 million in Q1 2024, with the low at $16.0 million in Q1 2026.
- The 5-year median for Total Current Liabilities is $32.6 million (2022), against an average of $42.7 million.
- The sharpest annual moves came in 2022 and 2025: Total Current Liabilities surged 167.93% in 2022, then tumbled 80.43% in 2025.
- Amylyx Pharmaceuticals' Total Current Liabilities stood at $46.6 million in 2022, then jumped by 76.02% to $82.0 million in 2023, then plunged by 65.38% to $28.4 million in 2024, then dropped by 20.13% to $22.7 million in 2025, then decreased by 29.63% to $16.0 million in 2026.
- Business Quant data shows AMLX's Total Current Liabilities at $16.0 million in Q1 2026, $22.7 million in Q4 2025, and $25.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.71 Bn | 42.75 Bn | - | -8.38 Bn |
| 2 | Teva Pharmaceutical Industries | 43.11 Bn | 39.45 Bn | 2.15 Bn | 15.65 Bn |
| 3 | Zoetis | 31.62 Bn | 29.94 Bn | 1.05 Bn | 2.06 Bn |
| 4 | Takeda Pharmaceutical | 28.72 Bn | 22.92 Bn | 5.10 Bn | 17.34 Bn |
| 5 | United Therapeutics | 22.33 Bn | 19.67 Bn | 683.80 Mn | 607.80 Mn |
| 6 | Viatris | 18.83 Bn | 17.95 Bn | 1.46 Bn | 6.35 Bn |
| 7 | Neurocrine Biosciences | 15.62 Bn | 15.23 Bn | 935.80 Mn | 874.50 Mn |
| 8 | Elanco Animal Health | 12.10 Bn | 11.57 Bn | 798.00 Mn | 1.85 Bn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | 1.79 Bn |
| 10 | Amylyx Pharmaceuticals | 4.28 Bn | 4.28 Bn | - | 21.15 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 21.15 Mn |
| Mar 31, 2026 | 15.97 Mn |
| Dec 31, 2025 | 22.69 Mn |
| Sep 30, 2025 | 25.79 Mn |
| Jun 30, 2025 | 21.42 Mn |
| Mar 31, 2025 | 17.93 Mn |
| Dec 31, 2024 | 28.41 Mn |
| Sep 30, 2024 | 53.92 Mn |
| Jun 30, 2024 | 70.08 Mn |
| Mar 31, 2024 | 91.64 Mn |
| Dec 31, 2023 | 82.04 Mn |
| Sep 30, 2023 | 45.62 Mn |
| Jun 30, 2023 | 64.08 Mn |
| Mar 31, 2023 | 51.62 Mn |
| Dec 31, 2022 | 46.61 Mn |
| Sep 30, 2022 | 32.65 Mn |
| Jun 30, 2022 | 27.16 Mn |
| Mar 31, 2022 | 27.71 Mn |
| Dec 31, 2021 | 17.40 Mn |